CAR T cells have been found to survive in the human body for up to three years or longer. Nonetheless, a relapse can occur even while the “living therapy” is still in the body. One major reason is that the cancer cells can loose the antigen that the CAR T cell is designed to hone in on. The loss of the antigen can be due to new genetic changes in the cancer cell or selective survival of cancer cell subpopulations (clones) that do not make that antigen.
National guidelines recommend testing lung tumor samples for changes in a whole range of cancer-related genes, as there are a number of matched targeted therapies available now.2 In reality, however, very few patients receive testing for more than one genomic abnormality, due to insufficient amount of tumor sample from the initial, diagnostic biopsy. There is some risk associated with tissue biopsies. For example, it is virtually impossible to perform a lung biopsy each time the cancer worsens. With the advent of noninvasive liquid biopsies that test for multiple genomic changes at a time, more patients may benefit from treatments tailored to the genetic makeup of the tumor.
Did you know that there are 10 microbe cells for every human cell in your body? An estimated 100 trillion microorganisms or microbes (bacteria, fungi, viruses and others) dwell in your gut alone!
Last year, the expected number of new cancer diagnoses in Ontario topped more than 85,000. In addition, the number of diagnoses and incidence rate of cancer has increased every year in Ontario since 1981. Two new studies in the Journal of Oncology Practice (JOP) examine practices in Ontario, Canada provide insights into the delivery of care in the province. The first study explores the financial impact of drug wastage, and the second describes the impact of immigration status on cancer outcomes.
Nearly every patient with cancer will go through a biopsy at some point. In fact, tumor biopsy is the main way doctors confirm a suspected cancer diagnosis. Pathologists look at the biopsy sample under a microscope to determine the type of cancer and how aggressively it may grow. These two pieces of information are critical for treatment planning.
ASCO’s Annual Meeting presents some of the most promising and exciting research in cancer care. It is here that researchers, clinicians, and advocates from around the globe gather for a first-hand look at research that will change practice and better inform clinical trials for years to come. Here’s a look at some of the highlights of this year’s Annual Meeting.
Twenty-five years in the making, the concept of redesigning T cells to eliminate cancer is still in its infancy. What will it take to bring CAR T-cell technology to routine cancer care? A key challenge to implementing wider use is managing the side effects patients often experience. While much more work lies ahead, recent research provides clues on how to make this approach safer.
The immune system is an intricate network of specialized cells and molecular messengers. Perfected by evolution, the immune system is arguably very good at keeping us alive and well… for the most part. Cancer is one exception.
The American Society of Clinical Oncology (ASCO) has released a Position Statement titled “Strategies for Reducing Cancer Health Disparities among Sexual and Gender Minority (SGM) Populations.” It was written by ASCO’s Health Disparities Committee, which was first created to tackle inequities in racial and ethnic minorities. Over the years, this committee has expanded its mission to address inequities in cancer care wherever they exist.
This week, Lancet Public Health published a study on the 2003 global tobacco control treaty’s impact on the adoption of tobacco reduction measures around the world, which has led to a 2.5% reduction in global smoking rates. The treaty obligates the 180 countries committed to it to implement strong evidence-based policies. While the U.S. signed on in 2004, it has never ratified this treaty.
We soundly oppose President Trump's budget outline, which would cut $6 billion from the National Institutes of Health (NIH). Reducing NIH's funding by nearly 20 percent will devastate our nation's already fragile federal research infrastructure and undercut a longstanding commitment to biomedical science that has fueled advances in cancer prevention, diagnosis, and treatment.
Experts estimate that at least one-third of all adult cancer cases are linked to lifestyle choices and habits, which include diet. While numerous studies have looked at food and cancer, it’s challenging to come away with definitive conclusions. Here are five commonly debated truths when it comes to food and cancer.
Many people associate surgery – removal of a tumor – as a critical step in a curative course of cancer treatment. Once the tumor is removed, following a course of radiation treatment, many also assume that what comes next is chemotherapy.
Recent advances in understanding the biology of lymphomas are helping spur new treatment approaches for patients. Cancer.Net Associate Editor in Lymphoma Dr. Michael E. Williams, chief of the Hematology/Oncology Division and director of the Hematologic Malignancies Program at the University of Virginia Cancer Center summarizes recent findings.
Lung cancer takes more than 1.5 million lives worldwide each year. This translates to 4,100 deaths per day, on average, nearly three a minute. Even in the modern era of targeted therapy, prospects of long-term survival remain elusive.